What are the major opportunities in the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market? What are the strategies for the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market?

For detailed insights on the major opportunities and strategies in the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market, Read More

How does the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market relate to the overall economy and other similar markets?

For detailed insights on Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market growth? SWOT analysis of the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market.

For detailed insights on the key dynamics influencing the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market growth and SWOT analysis of the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer industry, Read More

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Global Report 2026 Market Report Infographic Image

Published : March 2026

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report 2026

Name: Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy), By Stage (Stage I, Stage II, Stage III, Stage IV), By End-User (Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users) – Market Size, Trends, Strategies, and Forecast to 2035

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

• Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer market size has reached to $1.31 billion in 2025

• Expected to grow to $1.64 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%

• Growth Driver: Rising Adoption Of Targeted Cancer Therapy Fueling The Growth Of The Market Due To Advancements In Genetic Profiling

• Market Trend: FDA Approval Advances Immunotherapy For Gastric Cancer

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is a subtype of gastric (stomach) or gastroesophageal junction cancer in which the cancer cells have higher than normal levels of the human epidermal growth factor receptor 2 (HER2) protein or gene amplification, which promotes cancer cell growth. This subtype can be targeted with specific therapies, improving treatment outcomes in eligible patients.

The main therapy types for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer are chemotherapy, immunotherapy, radiation therapy, and targeted therapy. Chemotherapy uses powerful drugs that travel through the bloodstream to destroy fast-growing cancer cells, including those in HER2-positive gastric cancer. It is used for various stages, which include stage I, stage II, stage III, and stage IV, for varied end users such as ambulatory surgery centers, hospitals and specialty clinics, and others.

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Global Report 2026 Market Report bar graph

What Is The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Size and Share 2026?

The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market size has grown steadily in recent years. It will grow from $1.31 billion in 2025 to $1.37 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to limited availability of targeted therapies, reliance on conventional chemotherapy and radiation therapy, low awareness of her2-positive gastric cancer, restricted access to specialty clinics, slow adoption of immunotherapy.

What Is The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Growth Forecast?

The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market size is expected to see steady growth in the next few years. It will grow to $1.64 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to development of novel antibody-drug conjugates, increasing clinical trials for her2-targeted therapies, rising healthcare infrastructure in emerging markets, growth in precision medicine and biomarker testing, expanding ambulatory surgery centers and specialty oncology clinics. Major trends in the forecast period include increasing adoption of her2-targeted therapies, rising awareness of gastric cancer subtypes, expansion of immunotherapy and monoclonal antibody usage, growth in personalized treatment approaches, enhanced focus on early detection and diagnostic testing.

Book your 30 minutes free consultation with our research experts

Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Segmentation

1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy

2) By Stage: Stage I, Stage II, Stage III, Stage IV

3) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users

Subsegments:

1) By Chemotherapy: Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines

2) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies

3) By Radiation Therapy: External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy

4) By Targeted Therapy: HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors

What Is The Driver Of The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

The rising adoption of targeted cancer therapy is expected to propel the growth in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market going forward. Targeted therapy, also known as personalized medicine, is a treatment approach that uses specific drugs or substances to block the growth of cancer by focusing on particular molecules involved in tumor development. The rise in targeted therapy use is largely due to advancements in genetic profiling, which allow for more precise treatments based on an individual's unique tumor characteristics, leading to improved effectiveness and fewer side effects. In HER2-positive gastric cancer, targeted therapy is used by directly attacking the HER2 protein, which is overexpressed in these tumors, slowing disease progression and enhancing patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based professional membership organization, the Food and Drug Administration (FDA) approved 16 new personalized medicines, including 7 drugs for cancer and 3 for various other diseases and conditions in 2023, indicating an increase from 6 in 2022. Therefore, the rising adoption of targeted cancer therapy is driving the growth of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer industry.

Key Players In The Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

Major companies operating in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.

Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Trends and Insights

Major companies operating in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market are focusing on gaining approvals for innovative therapies such as advanced immunotherapy-enhanced combination regimens, such as the integration of immune checkpoint inhibitors with targeted therapy and chemotherapy, to significantly improve patient outcomes in first-line treatment settings. The advanced immunotherapy-enhanced combination regimens approach leverages the body's immune system by inhibiting programmed death (PD)-1 or programmed death (PD)-L1 interaction while simultaneously targeting HER2 receptors and using chemotherapeutic agents, thereby amplifying anti-tumor activity and enhancing survival rates. For instance, in March 2025, Merck & Co., Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for pembrolizumab (Keytruda), in combination with trastuzumab and chemotherapy, as a first-line treatment for adults with HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express programmed death (PD)-L1. This newly approved combination therapy demonstrated a substantial improvement in median progression-free survival and overall survival compared to standard regimens. With a higher overall response rate of 73% and a longer median duration of response, the treatment represents a paradigm shift in managing advanced HER2-positive gastric cancers.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

In December 2023, Pfizer Inc., a US-based pharmaceutical industry company, acquired Seagen Inc. for an undisclosed amount. Through this acquisition, Pfizer Inc. aims to strengthen its oncology portfolio, enhance its capabilities in targeted cancer therapies. Seagen Inc. is a US-based biotechnology company that specializes in HER2-positive gastric cancer treatments.

Regional Insights

North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market consists of sales of trastuzumab, pertuzumab, margetuximab, and lapatinib. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report 2026?

The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$1.37 billion
Revenue Forecast In 2035	$1.64 billion
Growth Rate	CAGR of 4.6% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Therapy, Stage, End-User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceuti
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Digitalization, Cloud, Big Data & Cybersecurity

4.1.3 Industry 4.0 & Intelligent Manufacturing

4.1.4 Artificial Intelligence & Autonomous Intelligence

4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Increasing Adoption Of Her2-Targeted Therapies

4.2.2 Rising Awareness Of Gastric Cancer Subtypes

4.2.3 Expansion Of Immunotherapy And Monoclonal Antibody Usage

4.2.4 Growth In Personalized Treatment Approaches

4.2.5 Enhanced Focus On Early Detection And Diagnostic Testing

5. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Analysis Of End Use Industries

5.1 Ambulatory Surgery Centers

5.2 Hospitals And Specialty Clinics

5.3 Oncology Research Centers

5.4 Pharmaceutical And Biotechnology Companies

5.5 Diagnostic Laboratories

6. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Size, Comparisons And Growth Rate Analysis

7.3. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Segmentation

9.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy

9.2. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Stage I, Stage II, Stage III, Stage IV

9.3. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users

9.4. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines

9.5. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies

9.6. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy

9.7. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors

10. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Regional And Country Analysis

10.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

11.1. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

12.1. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

13.1. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

14.1. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

14.2. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

15.1. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

16.1. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

17.1. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

17.2. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

18.1. Taiwan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

18.2. Taiwan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

19.1. South East Asia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

19.2. South East Asia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

20.1. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

20.2. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

21.1. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

22.1. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

23.1. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

24.1. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

25.1. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

26.1. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

26.2. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

27.1. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

28.1. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

28.2. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

29.1. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

29.2. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

30.1. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

30.2. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

31.1. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

31.2. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

32.1. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

33.1. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

33.2. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

34.1. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

34.2. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Regulatory and Investment Landscape

36. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Landscape And Company Profiles

36.1. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Company Profiles

36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

37. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Other Major And Innovative Companies

Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited, ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.

38. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

40. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market High Potential Countries, Segments and Strategies

40.1 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2030 - Countries Offering Most New Opportunities

40.2 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2030 - Segments Offering Most New Opportunities

40.3 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Overview Of Key Products - Product Examples

Table 2: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Supply Chain Analysis

Table 4: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Major Raw Material Providers

Table 5: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Major Resource Providers

Table 6: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Major Manufacturers (Suppliers)

Table 7: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Major Distributors And Channel Partners

Table 8: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Key Technologies & Future Trends

Table 9: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Major Trends

Table 10: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Major End Users

Table 11: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market - TAM, US$ Billion, 2025

Table 15: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Asia-Pacific, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Asia-Pacific, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Asia-Pacific, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: China, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: China, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: China, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: India, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: India, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: India, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: Japan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Japan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Japan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Australia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Australia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Australia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Indonesia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Indonesia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Indonesia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: South Korea, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: South Korea, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South Korea, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: Taiwan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: Taiwan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Taiwan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: South East Asia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: South East Asia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: South East Asia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: Western Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: Western Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Western Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: UK, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: UK, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: UK, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: Germany, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: Germany, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Germany, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: France, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: France, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: France, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: Italy, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Italy, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Italy, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Spain, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Spain, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Spain, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Eastern Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Eastern Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Eastern Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Russia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Russia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Russia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: North America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: North America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: North America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: USA, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: USA, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: USA, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: Canada, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: Canada, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Canada, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: South America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: South America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: South America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: Brazil, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Brazil, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Brazil, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Middle East, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Middle East, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Middle East, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Africa, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Africa, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Africa, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 97: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market - Company Scoring Matrix

Table 98: Pfizer Inc. Financial Performance

Table 99: Roche Holding AG Financial Performance

Table 100: Merck & Co Inc. Financial Performance

Table 101: Bayer Aktiengesellschaft Financial Performance

Table 102: Eli Lilly and Company Financial Performance

Table 103: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Competitive Benchmarking (In USD Billions)

Table 104: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Competitive Dashboard

Table 105: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 106: Global, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Size Gain ($ Billion), Segmentation By Therapy, 2025 – 2030

Table 107: Global, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Size Gain ($ Billion), Segmentation By Stage, 2025 – 2030

Table 108: Global, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Size Gain ($ Billion), Segmentation By End-User, 2025 – 2030

List Of Figures

Figure 1: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Overview Of Key Products - Product Examples

Figure 2: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Supply Chain Analysis

Figure 4: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Major Raw Material Providers

Figure 5: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Major Resource Providers

Figure 6: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Major Manufacturers (Suppliers)

Figure 7: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Major Distributors And Channel Partners

Figure 8: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Key Technologies & Future Trends

Figure 9: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Major Trends

Figure 10: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Major End Users

Figure 11: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market - TAM, US$ Billion, 2025

Figure 15: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Asia-Pacific, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Asia-Pacific, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Asia-Pacific, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: China, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: China, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: China, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: India, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: India, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: India, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: Japan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Japan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Japan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Australia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Australia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Australia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Indonesia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Indonesia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Indonesia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: South Korea, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: South Korea, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South Korea, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: Taiwan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: Taiwan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Taiwan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: South East Asia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: South East Asia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: South East Asia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: Western Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: Western Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Western Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: UK, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: UK, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: UK, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: Germany, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: Germany, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Germany, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: France, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: France, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: France, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: Italy, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Italy, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Italy, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Spain, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Spain, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Spain, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Eastern Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Eastern Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Eastern Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Russia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Russia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Russia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: North America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: North America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: North America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: USA, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: USA, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: USA, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: Canada, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: Canada, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Canada, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: South America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: South America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: South America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: Brazil, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Brazil, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Brazil, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Middle East, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Middle East, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Middle East, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Africa, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Africa, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Africa, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 97: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market - Company Scoring Matrix

Figure 98: Pfizer Inc. Financial Performance

Figure 99: Roche Holding AG Financial Performance

Figure 100: Merck & Co Inc. Financial Performance

Figure 101: Bayer Aktiengesellschaft Financial Performance

Figure 102: Eli Lilly and Company Financial Performance

Figure 103: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Competitive Benchmarking (In USD Billions)

Figure 104: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Competitive Dashboard

Figure 105: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 106: Global, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Size Gain ($ Billion), Segmentation By Therapy, 2025 – 2030

Figure 107: Global, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Size Gain ($ Billion), Segmentation By Stage, 2025 – 2030

Figure 108: Global, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Size Gain ($ Billion), Segmentation By End-User, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Gastric Cancer Diagnostic Procedure Market Report 2026 - Global Outlook – By Procedure Type (Endoscopic Procedure, Biopsy, Tissue Tests, Lab Tests, In-Vitro Diagnostic Tests, Imaging Tests, Molecular Diagnostics, Multipl...

Intestine Cancer Therapeutics Market Report 2026 - Global Outlook – By Treatment Type (Immunotherapy, Chemotherapy, Other Treatments), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By App...

Gastric Ulcers Market Report 2026 - Global Outlook – By Drug Class (Proton Pump Inhibitors (PPI), H2 Antagonists, Antacids, Antibiotics, Cytoprotective Agents, Other Drug Classes ), By Diagnosis (Stool Test, Endoscopy, I...

Gastrointestinal Stromal Tumor Market Report 2026 - Global Outlook – By Treatment Type (Chemotherapy, Targeted Therapy, Other Treatment Types), By Indication (Stomach, Small Intestine, Others Indications), By End-User (H...

Esophageal Cancer Market Report 2026 - Global Outlook – By Type (Esophageal Squamous-Cell Carcinoma, Esophageal Adenocarcinoma, Other Types), By Treatment Type (Chemotherapy, Targeted Therapy, Other Treatment Types), By ...

Gastroparesis Market Report 2026 - Global Outlook – By Treatment Modality (Medications, Dietary Modifications, Medical Devices, Other Therapies), By Gastroparesis Type (Idiopathic, Diabetic, Post- Surgical, Other Types),...

Cancer Biomarker Market Report 2026 - Global Outlook – By Biomarker Type (Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types), By Profiling Technologies (Omics Technologies, Immunoassay, Bioinformatics, Cytoge...

Frequently Asked Questions

How big is the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer market was valued at $1.31 billion in 2025, increased to $1.37 billion in 2026, and is projected to reach $1.64 billion by 2030.

What is the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer market growth?

The global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer market is expected to grow at a CAGR of 4.6% from 2026 to 2035 to reach $1.64 billion by 2035.

Who are the key players in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer market?

Some Key Players in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer market Include, Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd. .

What is the anticipated growth trend for the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer market?

Major trend in this market includes: FDA Approval Advances Immunotherapy For Gastric Cancer. For further insights on this market. request a sample here

Which region has the most growth potential in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer market?

North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.